Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Ischemic stroke caused by a thrombus clog and ischemia is one of the most lethal and disabling cerebrovascular diseases. A sequentially targeted delivery system is highly desired to deliver thrombolytics and neuroprotectant to the site of the thrombus and ischemic penumbra, respectively, to pursue a maximized combinational effect. Inspired by the vital roles that platelets play in thrombus formation, herein, we develop a bioengineered “nanoplatelet” (tP-NP-rtPA/ZL006e) for sequentially site-specific delivery of recombinant tissue plasminogen activator (rtPA) and neuroprotectant (ZL006e) for ischemic stroke treatment. The tP-NP-rtPA/ZL006e consists of a ZL006e-loaded dextran derivative polymeric nanoparticle core and platelet membrane shell conjugated with thrombin-cleavable Tat-peptide-coupled rtPA. Mediated by the cloak of the platelet membrane, tP-NP-rtPA/ZL006e targets the thrombus site and rtPA is triggered to release by the upregulated thrombin. Subsequently, the in situ exposed Tat peptide enhanced penetration of the “nanoplatelet” across the blood–brain barrier into ischemic brain for ZL006e site-specific delivery. From the in vitro and in vivo evaluation, tP-NP-rtPA/ZL006e is demonstrated to significantly enhance the anti-ischemic stroke efficacy in the rat model with middle cerebral artery occlusion, showing a 63 and 72% decrease in ischemic area and reactive oxygen species level compared to that with free drug combination, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reversible middle cerebral artery occlusion without craniectomy in rats.
Longa, E. Z., Weinstein, P. R., Carlson, S., & Cummins, R. (1989) · Stroke · doi:10.1161/01.str.20.1.84 · Cited by 7,463
Mechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926
Cited by
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Platelet-derived porous nanomotor for thrombus therapy
Wan, M., Wang, Q., Wang, R., Wu, R., Li, T., Fang, D., Huang, Y., Yu, Y., Fang, L., Wang, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9014 · Cited by 276
Self-citationDendrimer-Based Drug Delivery Systems for Brain Targeting
Zhu, Y., Liu, C., & Pang, Z. (2019) · Biomolecules · doi:10.3390/biom9120790 · Cited by 220
Bioactive Ceria Nanoenzymes Target Mitochondria in Reperfusion Injury to Treat Ischemic Stroke
Liao, J., Li, Y., Fan, L., Sun, Y., Gu, Z., Xu, Q.-Q., Wang, Y., Xiong, L., Xiao, K., Chen, Z.-S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c10982 · Cited by 104
Self-citationLi, J., Wei, Y., Zhang, C., Bi, R., Qiu, Y., Li, Y., & Hu, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020621 · Cited by 85
Metadata
- Authors
- Xu, J., Wang, X., Yin, H., Cao, X., Hu, Q., Lv, W., Xu, Q., Gu, Z., & Xin, H.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-07-24
- Volume
- 13
- Issue
- 8
- Pages
- 8577-8588
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2963292034
- Cited by
- 198
- References
- 2
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke. https://app.cochat.ai/papers/10.1021/acsnano.9b01798
- The paper
- Xu, J., Wang, X., Yin, H., Cao, X., Hu, Q., Lv, W., Xu, Q., Gu, Z., & Xin, H. (2019). Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke. ACS Nano. https://doi.org/10.1021/acsnano.9b01798
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.